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Background: The development of an asexual blood stage vaccine against Plasmodium falciparum malaria based on
the major merozoite surface protein-1 (MSP1) antigen is founded on the protective efficacy observed in preclinical
studies and induction of invasion and growth inhibitory antibody responses. The 42 kDa C-terminus of MSP1 has
been developed as the recombinant protein vaccine antigen, and the 3D7 allotype, formulated with the Adjuvant
System AS02A, has been evaluated extensively in human clinical trials. In preclinical rabbit studies, the FVO allele of
MSP142 has been shown to have improved immunogenicity over the 3D7 allele, in terms of antibody titres as well
as growth inhibitory activity of antibodies against both the heterologous 3D7 and homologous FVO parasites.
Methods: Two Phase 1 clinical studies were conducted to examine the safety, reactogenicity and immunogenicity
of the FVO allele of MSP142 in the adjuvant system AS01 administered intramuscularly at 0-, 1-, and 2-months: one
in the USA and, after evaluation of safety data results, one in Western Kenya. The US study was an open-label, dose
escalation study of 10 and 50 μg doses of MSP142 in 26 adults, while the Kenya study, evaluating 30 volunteers, was
a double-blind, randomized study of only the 50 μg dose with a rabies vaccine comparator.
Results: In these studies it was demonstrated that this vaccine formulation has an acceptable safety profile and is
immunogenic in malaria-naïve and malaria-experienced populations. High titres of anti-MSP1 antibodies were
induced in both study populations, although there was a limited number of volunteers whose serum demonstrated
significant inhibition of blood-stage parasites as measured by growth inhibition assay. In the US volunteers, the
antibodies generated exhibited better cross-reactivity to heterologous MSP1 alleles than a MSP1-based vaccine (3D7
allele) previously tested at both study sites.
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Conclusions: Given that the primary effector mechanism for blood stage vaccine targets is humoral, the antibody
responses demonstrated to this vaccine candidate, both quantitative (total antibody titres) and qualitative
(functional antibodies inhibiting parasite growth) warrant further consideration of its application in endemic
settings.
Trial registrations: Clinical Trials NCT00666380
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A highly efficacious, long-lasting malaria vaccine argu-
ably requires a multistage immunogen that prevents in-
fection or, failing that, impedes development of clinical
disease. Towards this end, many of the research efforts
within the malaria vaccine development programme at
the Walter Reed Army Institute of Research (WRAIR) have
focused on developing recombinant protein Plasmodium
falciparum vaccine antigens which, when mixed with po-
tent adjuvants such as AS01, an Adjuvant System con-
taining 3-O-desacyl-4’-monophosphoryl lipid A (MPL)
and Quillaja saponaria Molina, fraction 21 (QS21)
in liposomes, can elicit protective immune responses.
Such antigens could then be combined with promising
circumsporozoite-based vaccine candidates such as adju-
vanted RTS,S which is currently in Phase 3 trials [1,2].
Merozoite surface protein-1 (MSP1), found on the sur-
face of merozoites, is one such protein, with the 42 kDa
C-terminal fragment developed as the vaccine antigen.
Since the 42 kDa fragment contains known B- and T-
cell cell epitopes [3,4], a MSP142 vaccine antigen may be
capable of conferring protection mediated by providing
antigen-specific T-cell help for B-cells and antibody pro-
duction as well as by stimulating effector T-cells and the
secretion of lymphokines. Both MSP142 and MSP119 are
established targets of protective immunity in animal
models, and in both murine and non-human primate
studies the protection afforded by vaccination with
MSP1 is strain specific [5,6]. The 3D7 allele of MSP142
has been under clinical development at WRAIR for over
10 years [7] with accumulated safety and reactogenicity
data from two trials conducted at WRAIR [8, unpub-
lished data J Cummings] and four trials in endemic areas
in Mali and Kenya [9-12]. In all studies, the vaccine can-
didate MSP142 formulated in AS02 (an Adjuvant System
containing MPL and QS21 in an oil-in-water emulsion)
was shown to have an acceptable safety profile and be
immunogenic. The Phase 1 dose-escalation study con-
ducted in 15 malaria-naïve adults at WRAIR in 2001
demonstrated induction of low levels of functional anti-
bodies able to inhibit growth of homologous 3D7 para-
sites in a growth inhibition assay (GIA) [8]. The
subsequent Phase 2 paediatric malaria vaccine study
conducted in Kenya failed to demonstrate protectiveefficacy against clinical disease [12], but significant pro-
tection was detected against a subset of parasites with
allelic homology with the vaccine [unpublished observa-
tions, C Ockenhouse].
Evidence from both preclinical and clinical studies
suggests that without significant cross-reactivity, vaccin-
ation with a single MSP1 allotype may not achieve broad
efficacy and actually may contribute to selection of alter-
nate alleles [13]. Therefore, researchers at WRAIR also
developed an MSP142 protein antigen based on the FVO
sequence. Preclinical studies have shown improved im-
munogenicity of the FVO antigen as compared to the
3D7 antigen in terms of antibody titres as well as growth
inhibitory activity of antibodies against both heterol-
ogous and homologous parasites [unpublished data,
E Angov]. Active vaccination of Aotus nancymai mon-
keys with Escherichia coli [14,15] or baculovirus-expressed
[16-18] adjuvanted, recombinant FVO MSP142 induces a
significant homologous protection. Molecular typing of
P. falciparum parasites from East and West Africa indicate
that >90% of the dominant circulating alleles are QKNG
and EKNG, i e, FVO-like and CAMP-like [unpublished
data, C Ockenhouse]; therefore, a vaccine that is based on
the FVO allotypes of the MSP142 vaccine antigen may
stand a better chance of inducing protection in popula-
tions living in endemic areas. Conducting these two vac-
cine trials back-to-back in the USA and Kenya allowed for
assessment and comparison of the safety of the FVO can-
didate in two different populations, as well as the capabil-
ity of the formulation to induce potentially protective
antibody responses.
Methods
Study design and population
Two first-in-human clinical studies were conducted to test
WRAIR’s FVO MSP142 recombinant protein antigen
(a vaccine antigen designated FMP010, for “falciparum
malaria protein #10”, herein referred to as MSP142) in 0.5
millilitres (mL) of the AS01 adjuvant System: one at the
Clinical Trials Center (CTC) at WRAIR in Silver Spring,
Maryland, USA and the other six months later at US
Army Medical Research Unit in Kenya (USAMRU-K) at
the KEMRI/Walter Reed Project’s Muriithi Wellde Clinical
Research Centre, Kombewa, Kenya. The US Phase 1 open-
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adults: six subjects to receive approximately 10 μg dose
MSP142 antigen in 0.5 mL AS01, and 20 subjects to re-
ceive 50 μg MSP142 antigen in 0.5 mL AS01. A Safety
Monitoring Committee (SMC) reviewed all safety data
after the first vaccination in the 10 μg dose group prior to
progression to the 50 μg group as well as after the second
vaccination with 50 μg MSP1/AS01 before moving for-
ward to the Kenya study. The Kenya study was a Phase 1,
double blind, randomized controlled study in which 30
malaria-exposed adults were randomized in a 2:1 fashion,
20 of whom received 50 μg of the MSP142 antigen adju-
vanted in 0.5 mL of AS01 while 10 received RabipurW ra-
bies vaccine (Novartis, Basel, Switzerland). In both studies,
the vaccination schedule was at 0, 28 and 56 days with
intramuscular route of administration in the deltoid
muscle of the non-dominant arm.
The primary objective was to assess the safety and
reactogenicity of the MSP142/AS01 candidate malaria
vaccine in healthy adults. This was measured by the fol-
lowing endpoints: occurrence and intensity of solicited
symptoms on day of vaccination and days 1 through 7
after each vaccination, occurrence and intensity of un-
solicited symptoms over a 30-day follow-up period (day
of vaccination plus 29 subsequent days) after each vac-
cination and occurrence of serious adverse events (SAEs)
during the study period. The secondary objective was to
measure and compare, by quantifying parasite lactate de-
hydrogenase (pLDH) in a growth inhibition assay (GIA),
the functional humoral immune responses induced by
MSP142/AS01. In the US study, these immune responses
were additionally compared to the humoral immune re-
sponse previously generated to MSP142 3D7 allele admi-
nistered with the AS02 Adjuvant System with the
endpoint being percent parasite growth inhibition in
GIA against homologous (FVO) and heterologous (3D7)
parasites at baseline and post-third vaccination. The ter-
tiary objective was to measure, by enzyme-linked immu-
noabsorbent assay (ELISA) as performed by the reference
centre Malaria Serology Laboratory (MSL) at WRAIR, the
humoral immune response induced by MSP142/AS01.
Additional tertiary endpoints were titres of antibodies to
MSP142 of FVO, 3D7, and CAMP (FUP) antigens as deter-
mined by ELISA.
Inclusion criteria included healthy, non-pregnant
adults able to participate for the length of the study. Ex-
clusion criteria included prior receipt of any investiga-
tional malaria vaccine, vaccine containing either QS-21
or MPL or both, use of any investigational or non-
registered drug or vaccine other than the study vaccine
within 30 days preceding the first dose of study vaccine,
administration of chronic immunosuppressants or other
immune-modifying drugs within six months of vaccin-
ation, any confirmed or suspected immunosuppressiveor immunodeficient condition or family history of con-
genital or hereditary immunodeficiency, chronic or ac-
tive neurologic disease including seizure disorder, history
of splenectomy, acute or chronic, clinically significant
pulmonary, cardiovascular, hepatic or renal functional
abnormality, as determined by physical examination or
abnormal baseline laboratory screening tests, acute dis-
ease at the time of enrolment, hepatomegaly, right upper
quadrant abdominal pain or tenderness, administration
of immunoglobulins and/or any blood products within
the three months preceding the first dose of study vac-
cine or planned administration during the study period,
pregnant or lactating female, suspected or known current
alcohol abuse/drug abuse, any history of allergic reaction or
anaphylaxis to previous vaccination, inability to make
follow-up visits or complete diary cards, allergy to kanamy-
cin, nickel, or imidazole. For the US study, any past history
of malaria or planned travel to malarious areas during the
study period was exclusionary. All subjects gave written
informed consent under non-coercive means. Both studies
were conducted under Good Clinical Practices, were
approved by the WRAIR Institutional Review Board and
the United States Army Medical Research and Materiel
Command Human Subjects Research Review Board, and
filed under the US Food and Drug Administration Investi-
gational New Drug (IND) application number 13638. In
addition, the Kenya study was reviewed by the Kenya
Medical Research Institute Ethical Review Committee.
Vaccine
The MSP142 antigen is the C-terminal 42-kDa portion of
the merozoite surface protein-1 (MSP1) from the FVO
strain of P. falciparum expressed in and purified from
BL21 DE3 cell E. coli then lyophilized and bottled under
cGMP conditions at the WRAIR BioProduction Facility
BPF) [7]. MSP142 is a single polypeptide encoding a
codon-harmonized sequence of 371 amino acids consist-
ing of 16 non-MSP1 amino acids fused to the N-terminus
of a 355 amino acid C- terminal MSP1 (representing base
pair (bp) 3834–4898 from the wild type MSP1 FVO se-
quence, Genbank Accession number: X03371, encoding
amino acids 1333–1688). The 16 non-MSP1 amino acids
comprise an N-terminal extension from the native
MSP142 encoding the translation initiation codon, plus six
histidine residues for Ni+2-NTA affinity chromatography
and a series of repeating glycine, serine residues for flex-
ible extension of the polyhistidines from the body of the
protein. Approximately 60 μg of MSP142 (FVO) antigen,
production lot number 1157, was packaged in sterile, sin-
gle dose vials, which then underwent lyophilization. Vials
were maintained at the BPF, stored at 2-8°C in a moni-
tored refrigerator.
The antigen was reconstituted with the Adjuvant System
AS01 (GlaxoSmithKline Biologicals, Rixensart, Belgium),
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QS21 (Antigenics, New York, NY, USA) and liposomes.
One vial of AS01 provides a dose volume of 0.5 mL of
Adjuvant System. Both antigen and Adjuvant System were
kept at 2-8°C in monitored refrigerators, and on vaccin-
ation days, the vials were placed on wet ice no longer than
four hours and mixed at the time of intramuscular admin-
istration. For the 10 μg dose, five vials of AS01 were mixed
with one vial of MSP142 antigen and 0.5 mL withdrawn
for injection, while for the 50 μg dose, one vial of AS01
was formulated with one vial of antigen.
Safety and reactogenicity
Solicited symptoms included local adverse events (pain,
erythema and swelling) and systemic adverse events
(fever, nausea, headache, malaise, myalgia, fatigue, and
arthralgia). All symptoms were graded on a scale to indi-
cate degree of functional impairment (Grade 0: no im-
pairment, Grade 1: easily tolerated, Grade 2: interferes
with daily activity, Grade 3: prevents daily activity) ex-
cept for injection site erythema and swelling, which were
graded as a physical measurement taken at the greatest
diameter of involvement (Grade 0: 0 mm, Grade 1: >1 -
< 20 mm, Grade 2: >20 - < 50 mm, Grade 3: > 50 mm),
and fever, which was graded on the following scale of
oral temperature: Grade 0: <37.5°C, Grade 1: >37.5- <
38°C, Grade 2: >38- < 39°C, Grade 3: >39°C. In the US
study, subjects were seen in clinic on day 1, 2, 3 and 7
for this assessment; a diary card was also kept on days
0–7. Kenyan subjects were seen by a study clinician on
day 0, 3, and 7; no diary cards were kept. Haematologic
and biochemical tests for safety were collected on days
0, 14, 28, 42, 56 and 70, and again at three months after
last vaccination. Serious adverse events were collected
throughout the entire study period. In order to optimize
medical care and adverse event data collection in the
Kenya study, volunteers were provided with an identifi-
cation card with emergency medical contacts and had
access to the clinical trial centre for medical care 24
hours a day for the duration of the study with provisions
for appropriate specialist referral.
Immunogenicity
Antibody titre by ELISA
IgG responses to the P. falciparum MSP142 FVO antigen
were measured using standard ELISA methodologies at
the Malaria Serology Lab (MSL) at WRAIR. Briefly,
plates were coated with 100 μ L/well of MSP142 antigen
at a concentration of 1.0 μg/mL, placed inside a humid-
ity chamber and incubated overnight (16–20 hrs) at 4oC.
Plates were washed four times with 1X PBS (pH 7.4)
containing 1% Tween-20 and blocked with 0.5% boiled
casein (Sigma, St. Louis, MO, USA). Plates were washed
four times with 1X PBS solution between all subsequentsteps except the development reaction. Serum samples
from vaccinees were serially diluted on each plate and
incubated at 22°C for 2 hrs. Peroxidase-labelled goat
anti–human IgG (KPL, Gaithersburg, MD, USA) was
added to each well at a 1:4,000 dilution and incubated
for 1 hr at 22°C. ABTS Peroxidase substrate (KPL,
Gaithersburg, MD, USA) was added to induce reaction
development. At the end of 1-hr incubation at 22°C, a
stop solution (20% sodium dodecyl sulphate) was added
and the plates were read using a Spectromax340PC plate
reader. The absorbance at 414 nm was determined for
each well and these data were applied to a fourparameter
logistic curve using SoftMax 4.8 (Molecular Devices,
Sunnyvale, CA, USA). The serum titre was defined as
the serum dilution at which the optical density (OD)
was equal to 1.0. The geometric mean antibody titre at
each time point was determined with 95% confidence
intervals.
Growth inhibitory assay (GIA)
Serum samples were dialysed in 50K MW cutoff mini-
dialysis units (MWCO Slide-A-Lyzer Mini-Dialysis Units
from Pierce, Rockford, IL) to remove any potential anti-
malarial drugs [19] and then heat inactivated for 20 min
at 56°C. Cooled serum samples were pre-absorbed with
5 μL of human red blood cells (RBC), at 50% haemato-
crit per 100 μL of serum for 1 hr and tested at 20%
serum concentration for growth inhibition by measuring
pLDH activity [20]. Parasitized RBC (pRBC) cultures of
both the FVO allele (homologous) and the 3D7 allele
(heterologous) at the early schizont stage were set up
with pre-immune and immune sera at a 0.3% parasit-
aemia and 1% haematocrit. Assay plates (384 well plates)
(Spectraplates, Perkin Elmer, Boston, MA, USA) were
sealed in bags containing 2.5% CO2, 2.5% O2, 90% N2
and incubated for 40 or 48 hrs (cycle time of 3D7 and
FVO parasites, respectively). Cultures were then har-
vested by adding 80 μL per well of PBS and spinning
plates for 10 min at 10,000 g. Once completed, 80 μL of
supernatant were removed and cell pellets frozen at
−30°C until analysis. To measure the amount of pLDH
activity, a substrate buffer containing 0.1 M Tris HCl, 50
mM Sodium-L-lactate, 0.255 Triton-X, 10 mg NBT, 10 μg/
mL 3-Acetylpyridine, and 10 U/mL diaphorase from
Clostridium klyiveri (all reagents from Sigma, St. Louis,
MO, USA) was added to the plates. Colorimetric measure-
ment at 650 nm was done after 30 min of reaction
time using the SpectraMax Plus 384 spectrophotometer
(Molecular Devices, Sunnyvale, CA, USA). Pre-vaccination
samples were run in parallel with the post-vaccination sam-
ples, and the calculation of growth inhibition was deter-
mined by using the formula: % inhibition = [1-[(OD
immune serum –OD RBC)/(OD pre-immune serum – OD
RBC)]] × 100. Subjects demonstrating ≥15% activity were
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values established previously from MSP1 vaccine studies
[8] and is a conservative estimate of non-specific, assay
related background inhibition.Antibody fine specificity by ELISA
Fine specificity of antibody responses was assessed
using recombinant MSP142 FVO, MSP142 3D7 and
MSP142 CAMP. Microtiter plate (Immulon-2 HB; Thermo
Labsystems, Franklin, MA, USA) wells were coated with
0.8 pmol of recombinant antigen in 100 μL of PBS and
incubated overnight at 4°C followed by blocking for 1 hr
at room temperature with 300 μL of blocking buffer (1%
Fraction V BSA in PBS). Sera were diluted serially with
blocking buffer and incubated for 2 hrs at room
temperature. Plates were washed four times with wash
buffer (0.05% Tween 20, 0.0025% Chlorohexidine in PBS)
using a microplate washer (Skan-Washer 300 version B,
Skatron Instruments, Sterling, VA, USA). Goat anti-human
IgG (H+ L)-alkaline phosphatase conjugate diluted to
1:1,000 (Promega, Madison, WI, USA) was added to each
well and incubated at room temperature for 1 hr.
p-Nitrophenyl phosphate substrate (Sigma, St. Louis, MO,
USA), was added to each well and the OD405 nm was mea-
sured after 60 min with a microplate reader (Molecular
Devices, Spectra-Max Plus 384, SoftMax Pro software).
The midpoint antibody titre was calculated as the serum
dilution that produced 1.0 optical density 247 (OD) unit
in the ELISA assay. For analyses comparing MSP142
fragment-specific antibody titres, the coating antigens were
normalized to one another.Assessed for elig
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Figure 1 Subject flow chart for Phase 1 study in the USA.Statistics
Safety data is descriptively reported and was compiled
by RTI International (Research Triangle Park, NC, USA).
SAS v9 was used for statistical analysis of humoral im-
munogenicity data with the exception of day 0 versus
day 70 GIA comparison in Kenyan adults (Minitab). A
mixed model with unstructured covariance structure is
used to compare geometric means of ELISA titres be-
tween two dosage groups. Kenward-Rogers’s method is
used to estimate the degree of freedom (DF). Post-hoc
testing includes examination of the group effect at each
time point, and the p value is adjusted using the Tukey’s
method for multiple comparisons. Baseline value is com-
pared prior to the model fitting to ensure the compar-
ability between the experimental groups, and excluded
from the model. Comparisons of inhibitory activity by
serum GIA and allelic ELISA analysis were conducted
using a two sample t-test. All data were log transformed
to stabilize the variance. The distributions of the trans-
formed data were checked to be approximately normal
before analysis.
Results
Participant flow and demographics
In Figure 1, the study flow diagram and the number of
screened, enrolled and withdrawn subjects in the US study
are presented. Approximately 70% of the enrolled subjects
were female with the mean age of 32 years. Thirty-nine
percent of the subjects reported Caucasian as race/
ethnicity while 31% identified as African-American, 12%
Hispanic, 8% Native American/Alaskan, 8% other and 4%
Asian. Recruitment and vaccination of six subjects in theibility (n=47)
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50 μg group starting three weeks later after safety review.
One subject in the low-dose group was withdrawn after
the first vaccination due to a prolonged intercurrent ill-
ness, and in the high-dose group, three subjects were lost
after the first vaccination. One left the Washington DC
area, and the remaining two were withdrawn by the prin-
cipal investigator (PI), both for non-serious adverse events
that are more fully described in the safety section. For the
Kenya study, a similar flow diagram is presented in
Figure 2. Forty-six percent of the enrolled subjects were
female with a mean age of 33 years. All the participants
were African with 90% being of Luo ethnicity and 10% of
Luhya ethnicity. Recruitment began February 2009 with
all vaccinations administered by April 2009. One subject
withdrew consent after the third vaccination for personal
reasons unrelated to adverse events.
Safety and reactogenicity
Tables 1, 2 and 3 summarize the local and systemic soli-
cited adverse events (AEs) detected after vaccination in
both studies. Regarding local AEs, in the US study, pain,
redness and swelling occurred at similar rates for both
10 and 50 μg doses, whereas in the Kenya study, pain
was the most common local adverse event following vac-
cination with both MSP142/AS01 and the rabies vaccine.
Most local events for both studies were mild to moder-











Enrolled in study 
(n=32)
Figure 2 Subject flow chart for Phase 1 study in Kenya.of vaccination, although in the US study, swelling of
grade 3 severity was not uncommon in both dose
groups. In Kenya, only one female subject experienced
grade 3 swelling and redness following the receipt of the
third dose of the MSP142/AS01 vaccine. The systemic
AEs occurring the most frequently in both studies were
fatigue, malaise, headache and myalgia. Overall, the sys-
temic events began approximately 12 hours after vaccin-
ation, lasting 24–36 hours. In the US study for both 10
and 50 μg doses, there was a slight increase in severity
and frequency of both local and systemic events from
the first to second vaccination but no further increase
with the third. In the Kenya study there was no consist-
ent increase or decrease in systemic AEs with either the
MSP142/AS01 or rabies vaccine. No vaccine-related ser-
ious adverse events (SAEs) occurred during either study.
In the US study, one female subject vaccinated with 50
μg MSP142/AS01, developed several pruritic, erythema-
tous maculopapules on the right (vaccinated) arm one
day post-immunization. The lesions were physically con-
sistent with insect bites, and the subject reported staying
in a hotel the night before that may have had infesta-
tions. These lesions spread to other extremities and
persisted at varying intensities. Biopsy of a lesion by a
dermatologist offered a differential diagnosis of arthro-
pod assault versus drug reaction. All safety laboratory
tests were normal except for increased eosinophil
counts, which were 628 cells/μL immediately prior to115)
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Table 1 Solicited adverse events post-vaccination





G1 G2 G3 G1 G2 G3
Pain
Immunization 1 3 2 0 10 6 2
Immunization 2 1 2 1 7 9 1
Immunization 3 3 1 0 10 2 3
Redness
Immunization 1 1 0 1 3 1 4
Immunization 2 1 0 1 1 2 4
Immunization 3 2 0 1 3 2 3
Swelling
Immunization 1 0 1 1 0 2 8
Immunization 2 0 1 2 3 2 6
Immunization 3 1 0 3 1 3 10
Fever
Immunization 1 2 0 0 1 1 1
Immunization 2 1 2 0 4 4 2
Immunization 3 2 0 0 3 5 0
Fatigue
Immunization 1 1 0 0 6 4 1
Immunization 2 1 1 1 5 7 2
Immunization 3 1 2 0 7 3 3
Nausea
Immunization 1 0 0 0 1 0 0
Immunization 2 1 1 0 1 1 0
Immunization 3 0 0 0 0 1 1
Headache
Immunization 1 2 1 0 3 3 1
Immunization 2 3 0 0 3 6 2
Immunization 3 1 2 0 2 6 2
Malaise
Immunization 1 1 0 0 4 1 2
Immunization 2 0 1 2 3 6 4
Immunization 3 0 2 0 4 5 3
Myalgia
Immunization 1 0 0 0 1 2 1
Immunization 2 2 0 0 4 5 2
Immunization 3 0 2 0 6 2 3
Joint Pain
Immunization 1 0 0 0 2 2 0
Immunization 2 0 1 0 3 2 2
Immunization 3 0 2 0 4 4 1
Table 2 Solicited adverse events post-vaccination





G1 G2 G3 G1 G2 G3
Pain
Immunization 1 14 6 0 6 0 0
Immunization 2 12 7 0 5 0 0
Immunization 3 10 4 0 4 0 0
Redness
Immunization 1 1 0 0 0 0 0
Immunization 2 3 0 0 2 0 0
Immunization 3 0 0 1 0 0 0
Swelling
Immunization 1 6 0 0 2 0 0
Immunization 2 3 0 0 2 0 0
Immunization 3 1 0 1 1 0 0
Fever
Immunization 1 0 0 0 0 0 0
Immunization 2 1 0 0 0 0 0
Immunization 3 1 0 0 0 0 0
Fatigue
Immunization 1 2 3 0 1 0 0
Immunization 2 1 1 0 1 0 0
Immunization 3 2 0 0 0 0 0
Nausea
Immunization 1 3 0 0 1 0 0
Immunization 2 0 1 0 0 0 0
Immunization 3 0 0 0 0 0 0
Headache
Immunization 1 8 4 0 1 0 0
Immunization 2 3 0 1 0 0 0
Immunization 3 4 2 0 0 1 0
Malaise
Immunization 1 2 1 0 0 0 0
Immunization 2 2 3 0 0 0 0
Immunization 3 1 1 0 0 0 0
Myalgia
Immunization 1 1 0 0 1 0 0
Immunization 2 1 2 0 0 0 0
Immunization 3 1 0 0 0 0 0
Joint Pain
Immunization 1 2 1 0 1 0 0
Immunization 2 1 2 0 0 0 0
Immunization 3 1 0 0 1 0 0
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Table 3 Summary of solicited adverse events post-
vaccination (day 0–7) for subjects vaccinated with 50 μg
MSP142/AS01
Phase 1 US: 50 μg MSP142/AS01 (N = 54#) n(%)
G1 G2 G3 Any
Pain 27 (50%) 17 (31%) 6 (11%) 50 (93%)
Redness 7 (13%) 5 (9%) 11 (20%) 23 (43%)
Swelling 4 (7%) 7 (13%) 24 (44%) 35 (65%)
Fever 7 (13%) 10 (19%) 3 (6%) 20 (37%)
Fatigue 18 (33%) 14 (26%) 6 (11%) 38 (70%)
Nausea 2 (4%) 2 (4%) 1 (2%) 5 (9%)
Headache 8 (15%) 15 (28%) 5 (9%) 28 (52%)
Malaise 11 (20%) 12 (22%) 7 (13%) 30 (56%)
Myalgias 11 (20%) 9 (17%) 6 (11%) 26 (48%)
Joint Pain 9 (17%) 8 (15%) 3 (6%) 20 (37%)
Phase 1 Kenya: 50 μg MSP142/AS01 (N = 59#) n(%)
G1 G2 G3 Any
Pain 36 (61%) 17 (29%) 0 (0%) 53 (90%)
Redness 4 (7%) 0 (0%) 1 (2%) 5 (8%)
Swelling 10 (17%) 0 (0%) 1 (2%) 11 (19%)
Fever 2 (3%) 0 (0%) 0 (0%) 2 (3%)
Fatigue 5 (8%) 4 (7%) 0 (0%) 9 (15%)
Nausea 3 (5%) 1 (2%) 0 (0%) 4 (7%)
Headache 15 (25%) 6 (10%) 1 (2%) 22 (37%)
Malaise 5 (8%) 5 (8%) 0 (0%) 10 (17%)
Myalgias 3 (5%) 2 (3%) 0 (0%) 5 (8%)
Joint Pain 4 (7%) 3 (5%) 0 (0%) 7 (12%)
*N represents the number of volunteers enrolled and who received the first
vaccination. For the US Phase 1, five volunteers received the second and third
vaccination with 10 μg MSP142/AS01. For the 50 μg MSP142/AS01 group, 20
received the first vaccination and 17 the second and third vaccination (#total
of 54). In the Kenya Phase 1 study, 20 volunteers received the first and second
vaccination with 50 μg MSP142/AS01 and 19 the third vaccination (#total of
59) while 10 volunteers received all three rabies vaccinations. Each volunteer is
only counted one time per vaccination time point and the highest recorded
grade for that AE is reported. G1 = Grade 1, G2 = Grade 2, G3 = Grade 3.
Grading system describes degree of functional impairment (Grade 0: no
impairment, Grade 1: easily tolerated, Grade 2: interferes with daily activity,
Grade 3: prevents daily activity). Injection site redness and swelling grading
were as follows: Grade 0: 0 mm, Grade 1: >1 - < 20 mm, Grade 2: >20 - < 50
mm, Grade 3: > 50 mm. Fever was graded by oral temperature: Grade 0:
<37.5°C, Grade 1: >37.5 - < 38°C, Grade 2: >38 - < 39°C, Grade 3: >39°C.
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http://www.malariajournal.com/content/12/1/29the first vaccination, which peaked two weeks post-
vaccination at 1,020 cells/μL. The subject was withdrawn
from further vaccinations, and the rash and eosinophilia
completely resolved without sequelae by five weeks post-
vaccination. A second subject (male) was withdrawn due
to persistent anaemia that began on the day of, but prior
to, first vaccination and persisted over the next two
weeks, ranging from 11.9-12.6 g/dL (grade 1). The sub-
ject was seen by a gastroenterologist and an upper and
lower gastrointestinal endoscopy with biopsies was
performed; all findings were normal. A haematologistreviewed the chart, and a possible diagnosis of alcohol-
induced bone marrow suppression was made, and the
subject was withdrawn from the study.
Humoral immunogenicity
Anti-MSP-142 antibodies titres by ELISA
The vaccine specific MSP142 FVO ELISA assay was per-
formed by the MSL and used MSP142 FVO as the plate
antigen. The geometric mean titres to both the 10 and
50 μg doses in the US study and the 50 μg dose and ra-
bies control in the Kenya study were calculated and plot-
ted on log scale with 95% confidence intervals (CIs) as
shown in Figure 3. No statistical model is fitted between
Kenya and US studies since the baseline antibody values
are significantly different.
For the US study, a longitudinally borderline signifi-
cant difference in geometric mean of ELISA titres be-
tween the two dosage groups (p = 0.0510) was observed.
As expected there was no difference in geometric mean
ELISA titres between the two dosage groups on day 0,
the baseline (p = 0.9560). There were only minor statisti-
cally significant differences in point-wise titres whereby
the titres for the 50 μg dose group were slightly higher
than 10 μg group: on day 28 (adjusted p = 0.0676) and
day 56 (adjusted p = 0.0477). In Kenyan adults, by longi-
tudinal analysis, the antibody titres induced by the 50 μg
dose of MSP142/AS01 were greater than for the rabies
group, (p < 0.0001). While for point-wise comparisons,
the MSP142/AS01 titres were higher than rabies at all time
points tested (p < 0.0001), except for day 0 (p = 0.64), day
14 (p = 0.09) and day 28 (p = 0.11).
Functional antibody responses (GIA)
Measurement of functional anti-MSP142 antibodies from
immunized subjects was carried out with both the hom-
ologous FVO, and heterologous 3D7, P. falciparum
strains (Figure 4). The net percentage inhibition is
reported since inhibition detected on day 0 samples are
subtracted from the responses measured for day 70 (see
equation in Methods). When sera from vaccinated
malaria-naïve subjects were tested by GIA against hom-
ologous parasites, there was no significant difference in
median percent inhibition for the 10 μg dose group (9%)
and the 50 μg dose group (5%), (p = 0.5899) with only
three subjects having inhibitory activities above a previ-
ously determined cut off of 15%. There was no detect-
able inhibition demonstrated against heterologous 3D7
parasites using this same assay (data not shown).
As shown in Figure 5, in Kenyan adults there was
no statistically significant difference in GIA activity
between the MSP142/AS01 group and the rabies group
(p = 0.3108). On day 70, only five out of 20 (25%) indivi-
duals receiving MSP142/AS01 and three out of 10 (30%)
individuals receiving rabies vaccine had activities above
10 µg MSP1/AS01 (US)
50 µg MSP1/AS01 (US)




















Figure 3 Antibody titres to MSP142 FVO by ELISA. Log ELISA OD 1.0 titres are reported as the geomean and 95% confidence intervals (CIs).
Hatched line and filled-in squares are Kenyan subjects receiving 50 μg MSP142 FVO/AS01, hatched lines and triangles are Kenyan subjects
receiving rabies vaccine, solid lines and filled in circles are US subjects receiving 10 μg MSP142 FVO/AS01 and solid line with open diamond are
US subjects receiving 50 μg MSP142 FVO/AS01. X axis is day of study and Y axis is dilution reporting an OD =1.0 of MSP142 specific antibody. Plate
antigen was the WRAIR E. coli expressed recombinant protein, MSP142 FVO.
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necessarily MSP142/AS01 vaccine related, and on the
whole, there was not a statistical difference between
mean inhibitions measured on day 70 compared to day
0 (p = 0.460). Like the US study, no detectable inhibition
was demonstrated against heterologous 3D7 parasites
(data not shown). When the functional antibodyFigure 4 Results of serum GIA for 10 μg and 50 μg MSP142
(FVO)/AS01 vaccine in malaria-naïve adults. Percent parasite
growth inhibition against P. falciparum FVO clone parasites from the
US MSP142 FVO/AS01 study. The net percent growth inhibition of
pre-and post third immunization sera obtained for 10 μg and 50 μg
MSP142/AS01 dose subjects is shown tested at 20% (v/v, final).
Dashed horizontal lines indicate the median response, while the
filled bars indicate the 25 and 75% quartiles. Individual responses are
represented as either filled circles for the 10 μg or filled squares for
the 50 μg dose subjects. P value calculated from two-tailed t-test.
Figure 5 Results of serum GIA against Plasmodium falciparum
FVO parasites for subjects receiving rabies vaccine and the 50
μg MSP142(FVO)/AS01 vaccines in both Phase 1 studies. Percent
parasite growth inhibition against the P. falciparum FVO clone
parasites, comparing serum antibody responses obtained from
Kenyan adults and US naïve subjects immunized with the 50 μg
dose of MSP142 FVO/AS01. Left panel are the day 0 and post third
immunization, day 70, responses from Kenya adults either receiving
the rabies comparator control vaccine or the 50 μg dose of MSP142
FVO/AS01. Right panel are the net percent growth inhibitory
responses for the US subjects receiving the 50 μg dose of MSP142
FVO/AS01. Dashed horizontal lines indicate median responses, while
the filled lines indicate the 25 and 75% quartiles. Individual
responses are represented as either filled circles for the Kenyan
adults receiving the rabies vaccine, filled triangles for the Kenyan
adults receiving the MSP142 FVO/AS01 vaccine or filled gray squares
for the US naïve subjects receiving the 50 μg dose MSP142
FVO/AS01.
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groups are compared, the activities are higher post-
vaccination in the Kenya study, but these findings are
complicated by the higher baseline levels of inhibition
in that malaria-exposed population.
Antibody fine specificities
For the US study, allele specific ELISAs were performed
to assess the ability of the MSP142/AS01 vaccine to in-
duce cross-reactive antibody responses against the heter-
ologous alleles of MSP142. To assess allele specificity of
the antibody response, sera from day 70 from the 50 μg
dose group as well as from the MSP142 (3D7)/AS02
study (8) were evaluated against the E. coli expressed re-
combinant MSP142 alleles (MSP142 FVO, 3D7, CAMP)
by ELISA. The log-transformed data from these assays
are shown in Figure 6 as the median and 25th and 75th
quartile. No significant differences in antibody titres
were detected between the 10 μg and 50 μg doses for ei-
ther vaccine (data not shown); however there was a statis-
tically significant difference in the ability of the 50 μg
doses of MSP142/AS01 compared to MSP142 (3D7)/AS02
to induce responses to both the FVO (p < 0.0001) and
CAMP (p = 0.0001), allotypes of MSP142 which reportedly
represent 90% of field isolates in Western Kenya. In
addition, the median value of the response induced by the
FVO MSP142/AS01 vaccine was greater when tested
against the heterologous 3D7 allotype than that induced by
the homologous MSP142 (3D7)/AS02 vaccine (p = 0.0279).Figure 6 Allele specific antibody titres to 50 μg MSP142 (FVO)/
AS01 vs 50 μg MSP142 (3D7)/AS02 post third immunization.
Comparison of MSP142 allele specific antibody responses induced by
immunization with 50 μg MSP142 3D7/AS02 and MSP142 FVO/AS01.
Log ELISA OD 1.0 titres are reported as the median and 25 and 75%
quartile antibody response. Hatched boxes indicate the antigen
specific antibody responses induced by the MSP142 3D7/AS02
vaccine, a study conducted at WRAIR in 2001 (reference 7), and
open boxes indicate the responses induced by the MSP142 FVO/
AS01 vaccine. Plate antigens were the WRAIR E. coli expressed
recombinant proteins, MSP142 3D7, FVO and CAMP alleles. P values
are calculated from two-tailed t-tests.Discussion
In these first-in-human studies, MSP142(FVO)/AS01 was
evaluated, first in 26 malaria-naïve adults in a dose-
escalation fashion, followed by administration of only the
50 μg dose to 20 malaria-exposed adults with a rabies
comparator vaccine given to 10 concomitantly enrolled
subjects. The MSP142/AS01 vaccine in both studies was
shown to be well tolerated, with the solicited AEs profile
similar to what has been seen with past studies of AS01 in
combination with other recombinant proteins [21-24].
In subjects in the US study, this vaccine formulation
proved to be equally immunogenic at both 10 and 50 μg
doses, with relatively similar antibody titres between the
two dosage groups at all time points. While not directly
comparable due to population differences and malaria
exposure, there were generally higher titres induced by
the 50 μg dose vaccine in the US study compared to the
same dose in the Kenya study. Given the relatively high
levels of antibodies to MSP142 at all time points mea-
sured in both the MSP142/AS01 and rabies vaccine
groups, it is possible that immune responses elicited in
Kenyan adults with significant malaria exposure may
interfere with the induction of antibody responses rela-
tive to the responses observed in US subjects. This issue
may be less relevant for young children who have had
less sustained malaria exposure and/or lower antibody
titres, and thus, in this context, the vaccine may not
have to overwrite clonally imprinted responses, i e, pre-
existing immunity [11]. For both studies, there was a
significant increase in MSP1-specific antibody titres
after the second vaccination but no further boosting of
responses after the third vaccination. This phenomenon
has been seen with other recombinant protein antigen/
adjuvant system vaccines in malaria-naïve adults [8,22],
although the quality of the antibody responses with re-
spect to avidity or subclass would require further evalu-
ation. Antibody titres also appeared to be relatively
stable through the follow-up period after the third
vaccination.
The role that MSP119 plays in the formation of the para-
sitic food vacuole [25] suggests that antibodies that are
directed against MSP119 may be able to interfere with the
intra-erythrocytic parasite development [26]. In order to
evaluate functional antibody responses induced by the
vaccine, the in vitro GIA was employed to measure the ef-
fect of antibody on parasite growth and development. In
both the US and Kenya studies, it appears that MSP142
FVO/AS01 is capable of inducing some functional GIA ac-
tivity in a few subjects when tested at 20% (v/v), primarily
directed against the homologous FVO parasites and not
the heterologous 3D7 P. falciparum parasites. In the previ-
ous clinical trial using the alternative allele, MSP142 3D7/
AS02 [8], albeit with a different Adjuvant System, three
out of five subjects from the 50 μg dose achieved similar
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allele parasites; however, when this same vaccine was
tested in 200 children aged 12 to 48 months residing in
Western Kenya in a Phase 2 trial, there was no apparent
efficacy [12]. Evaluation of their immune serum tested at
5% (v/v) showed no vaccine-related GIA activity; however
significant inhibition was detected predominantly toward
FVO allele parasites, which were not vaccine related and
most likely due to natural exposure [manuscript in prepar-
ation, E Angov]. Other trials with MSP1 vaccine candi-
dates have reported similar discordance between the
magnitude of antibody titres and functional GIA activity
[15,27,28].
Although the functional antibodies detected by GIA to
blood-stage vaccine antigens such as MSP142 have been
proposed as putative surrogates of antigen quality and
protective potential, there is little direct evidence support-
ing this concept outside of findings from epidemiologic
studies evaluating the relationship of MSP1 antibody titres
and functional inhibition by GIA with reduced parasite
densities or clinical disease [29-33]. Studies from endemic
areas suggest that the acquisition of inhibitory antibodies
may be dependent upon the target antigen (MSP1,
AMA1, etc.) [31], and the age of the individual whereby
growth inhibitory activity had an inverse association with
increasing age [29,31,32]. In a study in Kenyan children
and adults, increased levels of growth inhibitory antibodies
correlated with a modest delay to time to infection but
only in younger children [29]. Similar findings were re-
cently also reported for West Africa where reduced mal-
aria risk in children and the presence of inhibitory
antibodies contributed to, but were not solely implicated
in, the acquisition of protective immunity [33]. Conversely,
in a longitudinal study of children and adults in Kenya
[31], support for a link between levels of MSP1-specific
antibodies, growth inhibition and risk of symptomatic
malaria was not observed. Further complicating this pic-
ture is the existence of “blocking” antibodies, which
“block” the ability of “inhibitory” antibodies to act against
the parasite as well as neutral antibodies, those that do not
inhibit nor block [34]. Several studies report that children
naturally exposed to malaria may develop both blocking
and/or neutral antibodies to MSP1 in addition to inhibi-
tory antibodies [35,36]. Thus the humoral immune re-
sponse induced in malaria-naïve vaccinated subjects may
differ qualitatively from those living in endemic areas who
may already have established blocking and/or neutral anti-
body specificities.
It should be cautioned that one should not rely solely
on an unvalidated in vitro functional assay such as the
GIA when making clinical development decisions on
progression of blood stage vaccine candidates. Since no
surrogate markers of protection have been identified
using active immunization, it is not known whether theabsence of significant GIA responses in this study is
meaningful. Induction of antibodies that function to in-
hibit erythrocyte invasion in malaria-experienced popu-
lations is influenced by many factors, including age and
transmission level, as well as the heterogeneity of circu-
lating parasite strains, and since malaria parasites appear
to use redundant invasion pathways, the current GIA
readout methods may not fully capture the complete
effect of anti-parasite activity. The malaria vaccine
researchers at WRAIR are currently re-examining the
allele-specific effects from the Phase 2 study that used
the 3D7 MSP142/AS02 formulation in order to assess
whether specific parasite genotypes in breakthrough
malaria infections in the vaccinated group signified se-
lection against the vaccine strain [12]. In addition, the
evaluation of new surrogate functional assays is urgently
required to assist in down selection of promising blood
stage vaccine candidates. Towards this end, the WRAIR
has recently improved the development of a promising
new functional in vivo assay which measures the ability
of passively transferred human immunoglobulin to pro-
tected mice challenged with transgenic Plasmodium
berghei parasites containing the p19 of P. falciparum
D10 strain [37]. The advantage of such a transgenic
model is that immune effectors cells are present, thus
enabling participation of Fc-receptor positive cells in the
clearance of the parasite as proposed previously [38,39].
In addition to the current formulations, alternative vac-
cine platforms such as particle-based delivery and/or
viral vectors could enhance the immunogenicity of
MSP1 and increase its utility as a component of second-
generation malaria vaccines.
Conclusions
The results from these two first-in-human studies of
MSP142 FVO/AS01 are encouraging; the vaccine was of
acceptable tolerability and is able to generate high titres
of FVO-specific antibodies, FVO-like parasites being the
predominant circulating P. falciparum MSP1 allotypes
in western Kenya. While the GIA assay results were not
as robust as had been hoped, there is still uncertainty in
the interpretation of the GIA as a surrogate marker of
blood stage immunity. In addition, the ability of the
FVO MSP1 vaccine to induce significant cross-reactive
antibodies against heterologous alleles provided encour-
agement for continued advancement of this vaccine
candidate.
Competing interests
MCD, OG, JC and WRB are employees of GlaxoSmithKline Biologicals s.a.
(GSK). They own shares and options to shares in GSK. In addition JC and
WRB are listed as inventors of patented malaria vaccines, but do not hold a
patent for a malaria vaccine. Specifically EA and JC are listed as inventors on
patent for this MSP142FVO antigen. The Study Sponsor was the Office of the
Surgeon General, US Army. This study was funded by the US Agency for
International Development (USAID), with partial support from
Otsyula et al. Malaria Journal 2013, 12:29 Page 12 of 13
http://www.malariajournal.com/content/12/1/29GlaxoSmithKline Biologicals (GSK) and the US Army Medical and Materiel
Research Command (USAMRMC). There are no other competing interests.
Authors’ contributions
EA and FK developed and manufactured the MSP1 vaccine antigen while
MCD, OG, JC, WRB are employees of GSK who provided the adjuvant system.
The studies were designed by NO, EA, OG, MK, MCD, WRB, LS, CD, JC, MP,
DGH, CFO and MDS. The principal investigators were NO and MDS and MK,
JB, LO, JC, BA, DT, WO, GAO, BO, MP, and CFO helped execute the clinical
trials. NO, MK, LW, MCD, MP and MDS were involved in regulatory aspects of
the vaccine and study. The immunological assays were conducted by EA,
EBL, JB, JW, NR, BH while EA, EBL, MS and MDS were involved in data
analysis All authors have read and approved the final manuscript.
The opinions or assertions contained herein are the private views of the
authors, and are not to be construed as official or as reflecting the views of
the Department of the Army or the Department of Defense.
Acknowledgements
We would like to thank the volunteers who participated in this study and
gave their time and effort to help in the malaria vaccine effort as well as the
clinical trial staff at WRAIR and KEMRI Walter Reed Project who worked to
make these studies run smoothly and correctly. A special thank you to the
medical monitors, Dr Paul Keiser and Dr Amos Otedo, the Safety Monitoring
Committee members Dr Elisa Malkin, COL James Veazey, MAJ James Moon,
as well as Dr Jeffrey Lyon, formerly of WRAIR, for his contribution to the
development of the vaccine, and Ms Tilly Levy and Ms Denise McKinney
from USAMMDA, USAMRMC. Finally we would like to extend our deep
appreciation to the Director of KEMRI, the USAMRU-K Commanders in
Nairobi and Kisumu, Kenya, and to Mrs Agnes Onyango for their support and
administration.
Author details
1Walter Reed Project, Kenya Medical Research Institute, Kisumu, Kenya.
2Malaria Vaccine Branch, Walter Reed Army Institute of Research, 2460
Linden Lane, Bldg #503, Silver Spring, USA. 3GlaxoSmithKline Biologicals, Rue
de l’Institut 89, Rixensart, Belgium. 4US Agency for International
Development, 1300 Pennsylvania Avenue, Washington DC 20523, USA.
Received: 17 August 2012 Accepted: 14 January 2013
Published: 23 January 2013
References
1. RTS,S Clinical Trial Partnership: First results of Phase 3 trial of RTS,S/AS01
malaria vaccine in African children. N Engl J Med 2011, 365:1863–1875.
2. Heppner DG Jr, Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA,
Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF,
Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L,
Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S,
Gettyacamin M, Diggs C, Soisson L, et al: Towards an RTS,S-based, multi-
stage, multi-antigen vaccine against falciparum malaria: progress at the
Walter Reed Army Institute of Research. Vaccine 2005, 18:2243–2250.
3. Hui GS, Gosnell WL, Case SE, Hashiro D, Nikaido C, Hashimoto A, Kaslow DC:
Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium
falciparum merozoite surface protein 1 (MSP1), YMSP119 expressed in
S. cerevisiae. J Immunol 1994, 153:2544–2553.
4. Udhayakumar V, Anyona D, Kariuki S, Shi YP, Bloland PB, Branch OH, Weiss W,
Nahlen BL, Kaslow DC, Lal AA: Identification of T and B cell epitopes
recognized by humans in the C-terminal 42-kDa domain of the Plasmodium
falciparum merozoite surface protein (MSP1). J Immunol 1995,
154:6022–6030.
5. Renia L, Ling IT, Marussig M, Miltgen F, Holder AA, Mazier D: Immunization
with a recombinant C-terminal fragment of Plasmodium yoelii merozoite
surface protein 1 protects mice against homologous but not heterologous
P. yoelii sporozoite challenge. Infect Immun 1997, 65:4419–4423.
6. Lyon JA, Angov E, Kay MP, Sullivan JS, Giroud AS, Robinson SJ, Bergmann-Leitner ES,
Duncan EH, Darko CA, Collins WE, Long CA, Barnwell JW: Protection induced
by Plasmodium falciparum MSP142 is strain-specific, antigen and adjuvant
dependent, and correlates with antibody responses. PLoS One 2008, 3:e2830.
7. Angov E, Aufiero BA, Van Handenhove M, Ockenhouse CF, Kester K, Walsh D,
McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DH, Ballou WR,
Diggs CL, Lyon JA: Development and preclinical analysis of a recombinant P.falciparum Merozoite Surface Protein-142 malaria vaccine. Mol Biochem
Parasitol 2003, 128:195–204.
8. Ockenhouse CF, Angov EA, Kester KE, Diggs C, Soisson L, Cummings JF,
Stewart VA, Palmer DP, Mahajan B, Krzych U, Tornieporth N, Delchambre M,
Vanhandenhove M, Ofori-Anyinam O, Cohen J, Lyon JA, Heppner DG: Phase 1
safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum
MSP-1 asexual blood stage vaccine. Vaccine 2006, 24:3009–3017.
9. Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M,
Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA,
Angov EA, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA,
Diggs CL, Wittes J, Heppner DG: Phase 1 randomized double-blind safety
and immunogenicity trial of Plasmodium falciparum malaria merozoite
surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in
western Kenya. Vaccine 2006, 25:176–184.
10. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert
DJ, Heppner DG, Stewart VA, Angov EA, Soisson L, Leach A, Tucker K,
Lyke KE, Plowe CV, Mali FMP1 Working Group: Safety and allele specific
immunogenicity of a malaria vaccine in adults: Results of a Phase 1
randomized trial. PLoS Clin Trials 2006, 1:e34.
11. Withers MR, McKinney D, Ogutu BR, Waitumbi JN, Milman JB, Apollo OJ,
Allen OG, Tucker K, Soisson LA, Diggs C, Leach A, Wittes J, Dubovsky F,
Stewart VA, Remich SA, Cohen J, Ballou WR, Holland CA, Lyon JA, Angov EA,
Stoute JA, Martin SK, Heppner DG, MSP-1 Malaria Vaccine Working Group:
Safety and Reactogenicity of an MSP-1 malaria vaccine candidate: A
randomized Phase 1b dose escalation trial in Kenyan children. PLoS Clin
Trials 2006, 1:e32.
12. Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K,
Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB,
Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J,
Ballou WR, Martin SK, Angov EA, Stewart VA, Lyon JA, Heppner DG, MR for
the MSP-1 Malaria Vaccine Working Group: Blood stage malaria vaccine
eliciting high antigen-specific antibody concentrations confers no
protection to young children in Western Kenya. PLoS One 2009, 4:e4708.
13. Genton B, Betuela I, Felger I, Al-Yaman A, Anders RF, Saul A, Baea K, Mellombo M,
Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP: A
recombinant blood stage malaria vaccine reduces Plasmodium falciparum
density and exerts selective pressure on parasite populations in a Phase 1-2b
trial in Papua New Guinea. J Infect Dis 2002, 185:820–827.
14. Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW: Biochemical
and immunological characterization of bacterially expressed and
refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite
surface protein 1. Infect Immun 2003, 71:6766–6774.
15. Darko CA, Angov E, Collins WE, Bergmann-Leitner ES, Girouard AS, Hitt SL,
McBride JS, Diggs CL, Holder AA, Long CA, Barnwell JW, Lyon JA: Clinical
grade Plasmodium falciparum FVO MSP142 Expressed in Escherichia coli
protects Aotus nancymai against homologous erythrocytic-stage
challenge. Infect Immun 2005, 73:287–297.
16. Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro
CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT, Hui GS: A
recombinant baculovirus 42-kilodalton C-terminal fragment of
Plasmodium falciparum merozoite surface protein 1 protects Aotus
monkeys against malaria. Infect Immun 1996, 64:253–261.
17. Stowers AW, Chen LH, Zhang Y, Kennedy MC, Zou L, Lambert L, Rice TJ,
Kaslow DC, Saul A, Long CA, Meade H, Miller LH: A recombinant vaccine
expressed in the milk of transgenic mice protects Aotus monkeys from a
lethal challenge with Plasmodium falciparum. Proc Natl Acad Sci USA 2002,
99:339–344.
18. Stowers AW, Cioce V, Shimp RL, Lawson M, Hui G, Muratova O, Kaslow DC,
Robinson R, Long CA, Miller LH: Efficacy of two alternate vaccines based
on Plasmodium falciparum merozoite surface protein 1 in an Aotus
challenge trial. Infect Immun 2001, 69:1536–1546.
19. Persson KE, Lee CT, Marsh K, Beeson JG: Development and optimization of
high throughput methods to measure Plasmodium falciparum-specific
growth inhibitory antibodies. J Clin Microbiol 2006, 44:1665–1673.
20. Bergmann-Leitner ES, Duncan EH, Burge JR, Spring M, Angov E:
Miniaturization of a high-throughput pLDH-based Plasmodium
falciparum growth inhibition assay for small volume samples from
preclinical and clinical vaccine trials. Am J Trop Med Hyg 2008, 78:468–471.
21. Polhemus ME, Remich SA, Ogutu BR, Waitumbi JN, Otieno L, Apollo S,
Cummings JF, Kester KE, Ockenhouse CF, Stewart A, Ofori-Anyinam O,
Ramboer I, Cahill CP, Lievens M, Dubois MC, Demoitie MA, Leach A, Cohen
Otsyula et al. Malaria Journal 2013, 12:29 Page 13 of 13
http://www.malariajournal.com/content/12/1/29J, Ballou WR, Heppner DG Jr: Evaluation of RTS, S/AS02A and RTS, S/
AS01B in adults in a high malaria transmission area. PLoS One 2009,
4:e6465.
22. Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reideler R, Angov E,
Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MK,
Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein
RW, De Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K,
Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, et al: Phase 1/2a
study comparing the safety, immunogenicity and efficacy of the malaria
vaccine candidate Apical Membrane Antigen-1 (AMA-1) in adjuvant
AS01B or AS02A in malaria-naïve adults. PLoS One 2009, 4:e5254.
23. Cummings JF, Spring MD, Schwenk RJ, Ockenhouse CF, Kester KE, Polhemus
ME, Walsh DS, Yoon IK, Prosperi C, Juompan LY, Lanar DE, Krzych U, Hall BT,
Ware LA, Stewart VA, Williams J, Dowler M, Nielsen RK, Hillier CJ, Giersing
BK, Dubovsky F, Malkin E, Tucker K, Dubois MC, Cohen JD, Ballou WR,
Heppner DG: Recombinant Liver Stage Antigen-1 (LSA-1) formulated
with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-
gamma/IL-2 CD4+ T cells but does not protect against experimental
Plasmodium falciparum infection. Vaccine 2009, 28:5135–5144.
24. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris
P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J,
Dowler M, Stewart VA, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou WR,
Heppner DG Jr, RTS, S Vaccine Evaluation Group: Randomized, double-
blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and
RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic
associates of protection. J Infect Dis 2009, 200:337–346.
25. Dluzewski AR, Ling IT, Hopkins JM, Grainger M, Margos G, Mitchell GH,
Holder AA, Bannister LH: Formation of the food vacuole in Plasmodium
falciparum: a potential role for the 19 kDa fragment of merozoite surface
protein 1 (MSP1(19)). PLoS One 2008, 3:e3085.
26. Bergmann-Leitner ES, Duncan EH, Angov E: MSP-1p42-specific antibodies
affect growth and development of intra-erythrocytic parasites of
Plasmodium falciparum. Malar J 2009, 8:183.
27. Malkin E, Long CA, Stowers AW, Zou L, Singh S, MacDonald NJ, Narum DL,
Miles AP, Orcutt AC, Muratova O, MOretz SE, Zhou H, Diouf A, Fay M,
Tierney E, Leese P, Mahanty S, Miller LH, Saul A, Marton LB: Phase 1 study
of two merozoite surface protein 1 (MSP142) vaccines for Plasmodium
falciparum malaria. PLoS Clin Trials 2007, 2:e12.
28. Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, Narum DL, Zhu D,
Mullen GED, Mahanty S, Miller LH, Durbin AP: Phase 1 trial of the
Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel
with and without CPG 7909 in malaria naïve adults. PLoS One 2010,
5:e8787.
29. Dent AE, Bergmann-Leitner ES, Wilson DW, Tisch DJ, Kimmel R, Vulule J,
Sumba PO, Beeson JG, Angov EA, Moormann AM, Kazura JW: Antibody-
mediated growth inhibition of Plasmodium falciparum: relationship to
age and protection from parasitemia in Kenyan children and adults.
PLoS One 2008, 3:e3557.
30. Perraut R, Marrama L, Diouf B, Sokhna C, Tall A, Nabeth P, Trape JF,
Longacre S, Mercereau-Puijalon O: Antibodies to the conserved C-terminal
domain of the Plasmodium falciparum merozoite surface protein 1 and
to the merozoite extract and their relationship with in vitro inhibitory
antibodies and protection against clinical malaria in a Senegalese
village. J Infect Dis 2005, 191:264–271.
31. Courtin D, Oesterholt M, Huismans H, Kusi K, Milet J, Badaut C, Gaye O,
Roeffen W, Remarque EJ, Sauerwein R, Garcia A, Luty AJF: The quantity and
quality of African children’s IgG responses to merozoite surface antigens
reflect protection against Plasmodium falciparum malaria. PLoS One 2009,
4:e7590.
32. McCallum FJ, Persson KE, Mugyenyi CK, Fowkes FJ, Simpson JA, Richards JS,
Williams TN, Marsh K, Beeson JG: Acquisition of growth-inhibitory
antibodies against blood-stage Plasmodium falciparum. PLoS One 2008,
3:e3571.
33. Crompton PD, Miura K, Traore B, Kayentao K, Ongoiba A, Weiss G, Doumbo S,
Doumtabe D, Kone Y, Huang CY, Doumbo OK, Miller LH, Long CA, Pierce SK:
In vitro growth inhibitory activity and malaria risk in a cohort study in Mali.
Infect Immun 2010, 78:737–745.
34. Holder AA, Guevara Patiño JA, Uthaipibull C, Syed SE, Ling IT, Scott-Finnigan T,
Blackman MJ: Merozoite surface protein 1, immune evasion, and vaccines
against asexual blood stage malaria. Parassitologia 1999, 41:409–414.35. Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Odaibo AB, Holder AA,
Nwagwu M: The human immune response to Plasmodium falciparum
includes both antibodies that inhibit merozoite surface protein 1
secondary processing and blocking antibodies. Infect Immun 2002,
70:5328–5331.
36. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, Egwang TG,
Holder AA, Riley EM: Fine specificity of serum antibodies to Plasmodium
falciparum merozoite surface protein, PfMSP1(19), predicts protection
from malaria infection and high-density parasitemia. Infect Immun 2004,
72:1557–1567.
37. De Koning-Ward TF, O’Donnell RA, Drew DR, Thomson R, Speed TP, Crabb BS:
A new rodent model to assess blood stage immunity to the Plasmodium
falciparum antigen merozoite surface protein 119 reveals a protective role
for invasion inhibitory antibodies. J Exp Med 2003, 198:869–875.
38. Galamo CD, Jafarshad A, Blanc C, Druilhe P: Anti-MSP1 block 2 antibodies
are effective at parasite killing in an allele-specific manner by monocyte-
mediated antibody-dependent cellular inhibition. J Infect Dis 2009,
199:1151–1154.
39. McIntosh RS, Shi J, Jennings RM, Chappel JC, De Koning-Ward TF, Smith T,
Green J, Van Egmond M, Leusen JHW, Lazarou M, Van de Winkel J, Jones TS,
Crabb BS, Holder AA, Pleass RJ: The importance of human FcgammaRI in
mediating protection to malaria. PLoS Pathog 2007, 3:e72.
doi:10.1186/1475-2875-12-29
Cite this article as: Otsyula et al.: Results from tandem Phase 1 studies
evaluating the safety, reactogenicity and immunogenicity of the
vaccine candidate antigen Plasmodium falciparum FVO merozoite
surface protein-1 (MSP142) administered intramuscularly with adjuvant
system AS01. Malaria Journal 2013 12:29.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
